Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report

Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening complication caused by platelet activation via platelet factor 4 (PF4) antibodies. We report a healthy 28-year-old man who developed hemoptysis, bilateral leg pain, and headaches three weeks after his third dose of the C...

Full description

Bibliographic Details
Main Authors:	Tzu-Chien Lin, Pei-An Fu, Ya-Ting Hsu, Tsai-Yun Chen
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Vaccines
Subjects:	vaccine-induced immune thrombotic thrombocytopenia mRNA vaccine BNT162b2 COVID-19 vaccine booster
Online Access:	https://www.mdpi.com/2076-393X/11/6/1115

Similar Items

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
by: Moe H. Kyaw, et al.
Published: (2023-01-01)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
by: Tekin Guney, et al.
Published: (2022-02-01)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
by: Stilla Bauernfeind, et al.
Published: (2022-09-01)

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
by: Serkan Atıcı, et al.
Published: (2023-07-01)

Unilateral Pleural Effusion after Third Dose of BNT162b2 mRNA Vaccination: Case Report
by: Nikolaos K. Athanasiou, et al.
Published: (2023-02-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
by: Takeshi Terashima
Published: (2021-01-01)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
by: Eli Magen, et al.
Published: (2022-07-01)

Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine
by: Tiziana Grassi, et al.
Published: (2022-11-01)

Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components
by: Rosalia Busà, et al.
Published: (2022-03-01)

B-cell lymphoblastic lymphoma following intravenous BNT162b2 mRNA booster in a BALB/c mouse: A case report
by: Sander Eens, et al.
Published: (2023-05-01)

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
by: Passakorn Wanchaijiraboon, et al.
Published: (2023-02-01)

Effect of SARS-CoV-2 Infection and BNT162b2 Vaccination on the mRNA Expression of Genes Associated with Angiogenesis
by: Paulina Wigner-Jeziorska, et al.
Published: (2023-11-01)

Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccineResearch in context
by: Ivan Odak, et al.
Published: (2024-01-01)

Addendum: B-cell lymphoblastic lymphoma following intravenous BNT162b2 mRNA booster in a BALB/c mouse: a case report
by: Sander Eens, et al.
Published: (2023-10-01)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
by: Eun-Ju Kim, et al.
Published: (2023-06-01)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
by: Maria Eduarda Andrade e Andrade, et al.
Published: (2022-01-01)

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers
by: Khetam Hussein, et al.
Published: (2022-10-01)

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
by: Giuseppe A. Palumbo, et al.
Published: (2023-02-01)

A Case of COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia
by: Abhinandan Chittal, et al.
Published: (2021-11-01)

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
by: Suyanee Mansanguan, et al.
Published: (2022-08-01)

BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
by: Anna Kaznadzey, et al.
Published: (2022-04-01)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
by: Einat Shacham Shmueli, et al.
Published: (2022-08-01)

Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult
by: Mazin Barry, et al.
Published: (2022-01-01)

COVID-19 mRNA BNT162b2 vaccine safety and antibodies level among healthcare workers at Centre Hospitalier du Nord
by: Rosabelle Chedid, et al.
Published: (2022-04-01)

Effect of Heterologous Vaccination Strategy on Humoral Response against COVID-19 with CoronaVac plus BNT162b2: A Prospective Cohort Study
by: Hakan Demirhindi, et al.
Published: (2022-04-01)

Impact of Health Workers’ Choice of COVID-19 Vaccine Booster on Immunization Levels in Istanbul, Turkey
by: Meryem Merve Ören, et al.
Published: (2023-05-01)

Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
by: Hamad Ali, et al.
Published: (2021-11-01)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
by: Ahmed Zaqout, et al.
Published: (2021-07-01)

Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals
by: Zoltán Szekanecz, et al.
Published: (2023-11-01)

Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster
by: Napaporn Chantasrisawad, et al.
Published: (2022-12-01)

Cervical and Axillary Lymphadenopathy After Administrating mRNA BNT-162b2 Vaccine Against COVID-19: Clinical and Sonographic Findings, Outcomes of Short-term Follow-up
by: Umur Anıl PEHLİVAN, et al.
Published: (2022-06-01)

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
by: Manuela A. Hoffmann, et al.
Published: (2021-08-01)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
by: Jolanta Kiewisz, et al.
Published: (2022-04-01)

Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies
by: Shuailei Chang, et al.
Published: (2022-03-01)

Case report: Vaccine-induced immune thrombotic thrombocytopenia complicated by acute cerebral venous thrombosis and hemorrhage after AstraZeneca vaccines followed by Moderna COVID-19 vaccine booster and surgery
by: Quan-Ting Chen, et al.
Published: (2022-10-01)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
by: Toshio Naito, et al.
Published: (2022-01-01)

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccineResearch in context
by: Lorenzo Azzi, et al.
Published: (2023-02-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)